<DOC>
	<DOCNO>NCT01193153</DOCNO>
	<brief_summary>This study evaluate efficacy paliperidone palmitate compare placebo delay relapse symptom schizoaffective disorder . This study also assess safety tolerability paliperidone palmitate patient schizoaffective disorder .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Paliperidone Palmitate Prevention Relapse Symptoms Schizoaffective Disorder</brief_title>
	<detailed_description>Schizoaffective disorder chronic illness generally require life-long treatment . To date however , medication evaluate maintenance treatment schizoaffective disorder . This randomize ( study drug assign chance ) , double-blind ( neither physician patient know name assign drug ) , placebo-controlled , parallel-group , multicenter study evaluate efficacy safety paliperidone palmitate , monotherapy adjunct mood stabilizer antidepressant , relative placebo delay time relapse patient schizoaffective disorder . This study explore use paliperidone palmitate either monotherapy adjunct mood stabilizer antidepressant ( MS/AD ) treatment approach commonly use clinical management schizoaffective disorder . Patients acute symptom schizoaffective disorder enrol . The study consist 4 period : 7 day screening/tolerability period , 13-week open-label flexible dose lead-in period , 12-week open-label fix dose stabilization period , 15 month double-blind relapse prevention period . Patients without previous exposure paliperidone ER ( Invega ) , paliperidone palmitate ( Invega Sustenna ) , risperidone , RISPERDAL CONSTA give 4 6 day paliperidone ER 6mg/day tolerability test . Patients continue current antipsychotic regimen Day -1 ( day start study period ) . During open-label period , patient treat paliperidone palmitate . An initial loading dose 234 mg ( 150 mg eq . ) paliperidone palmitate give deltoid injection follow 156 mg ( 100 mg eq . ) deltoid injection Day 8 . Starting Day 36 , injection may administer either deltoid muscle gluteal muscle . Doses Days 36 , 64 92 may increase decrease within range 78 mg ( 50 mg eq . ) 234 mg ( 150 mg . eq . ) clinically indicate . Dose fixed ( Day 92 dose ) 12-week stabilization period . Patients meet pre-determined stabilization criterion eligible enter double-blind relapse prevention period randomly assign either receive paliperidone palmitate ( Day 92 dose ) placebo treatment . Patients intramuscular ( i.m . ) study drug injection efficay saftety evaluation perform every 4 week throughout study . Efficacy evaluate study use relapse assessment , Positive Negative Symptom Scale ( PANSS ) , Clinical Global Impression Severity Schizoaffective Disorder ( CGI-S-SCA ) , Personal Social Performance Scale ( PSP ) , Young Mania Rating Scale ( YMRS ) , Hamilton Rating Scale Depression ( HAM-D ) . Safety assess throughout study monitor adverse event , clinical laboratory test , electrocardiogram ( ECGs ) , vital sign measurement ( temperature , pulse , blood pressure ) , weight , monitor extrapyramidal symptom use Extrapyramidal Symptom Rating Scale-Abbreviated ( ESRS-A ) . Suicidality assess Columbia Suicide Severity Rating Scale ( C-SSRS ) . A 10 milliliter pharmacogenomic blood sample ( sample DNA research ) collect patient give separate write informed consent part study . Participation pharmacogenomic research optional . Blood sample take patient treated lithium valproate measurement blood lithium valproate level . Approximately 52 mL ( 31 mL patient receive lithium valproate ) whole blood collect study . All patient receive paliperidone palmitate 78 , 117 , 156 , 234 mg ( 50 , 75 , 100 , 150 mg eq . ) monthly i.m . injection first 25 week study ( open-label period ) . During 15-month double-blind relapse prevention period , one half patient randomize paliperidone palmitate treatment ( 50 , 75 , 100 , 150 mg eq . monthly i.m . injection ) half patient randomize monthly placebo injection .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>DSMIV diagnosis schizoaffective disorder Experiencing acute exacerbation psychotic symptom A score &gt; =4 least 3 follow 7 PANSS item : Delusions ( P1 ) , Hallucinatory behavior ( P3 ) , Excitement ( P4 ) , Hostility ( P7 ) , Tension ( G4 ) , Uncooperativeness ( G8 ) , Poor Impulse Control ( G14 ) A score &gt; =16 YMRS and/or score &gt; =16 HAMD21 Healthy base physical examination , electrocardiogram ( ECG ) , laboratory test , medical history , vital sign measurements A primary active mental illness diagnosis schizoaffective disorder Have attempt suicide within 12 month imminent risk suicide violent behavior Subjects first episode psychosis Received electroconvulsive therapy past 3 month History hypersensitivity intolerance paliperidone , risperidone , 20 % Intralipid ( placebo ) Received longacting antipsychotic medication within 2 injection cycle Received therapy clozapine within 3 month A history neuroleptic malignant syndrome Previous history lack response antipsychotic medication Subjects receive therapy antidepressant mood stabilizer initiate and/or change dose &lt; 30 day prior screen Receiving therapy carbamazepine Receiving therapy monoamine oxidase inhibitor Pregnant , breastfeeding , plan become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>schizoaffective disorder</keyword>
	<keyword>paliperidone palmitate</keyword>
	<keyword>INVEGA SUSTENNA</keyword>
	<keyword>schizoaffective disorder relapse prevention</keyword>
</DOC>